Stay updated on Dolatav Clinical Trial: Nucleoside Sparing in HIV-1

Sign up to get notified when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.
Latest website image capture
Clouds background image

Latest updates to the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page

  1. Check
    5 days ago
    Change Detected
    Summary
    The footer revision number changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-11T13:38:49.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the study record content with a standard error page and site chrome, indicating the study details are not accessible at this URL.
    Difference
    18%
    Check dated 2026-09-20T19:55:27.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    Revision label updated from v3.6.5 to v3.6.6. This represents a small administrative update to the study record and does not affect trial details or visible content.
    Difference
    0.1%
    Check dated 2026-08-30T16:50:37.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    Revision updated from v3.6.4 to v3.6.5. This indicates a lightweight update to the page’s text or underlying tooling.
    Difference
    0.1%
    Check dated 2026-08-09T08:46:28.000Z thumbnail image
  7. Check
    83 days ago
    Change Detected
    Summary
    The study record’s revision marker was updated from v3.6.3 to v3.6.4, representing an administrative update to the page rather than a change to the study content.
    Difference
    0.1%
    Check dated 2026-07-25T18:08:47.000Z thumbnail image
  8. Check
    104 days ago
    Change Detected
    Summary
    This update adds Revision: v3.6.3 and removes Revision: v3.6.2. It reflects a metadata-level release with no changes to the study data or front‑end content.
    Difference
    0.1%
    Check dated 2026-07-04T13:29:09.000Z thumbnail image

Stay in the know with updates to Dolatav Clinical Trial: Nucleoside Sparing in HIV-1

Enter your email address, and we'll notify you when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.